Evogene (EVGN) Competitors $1.33 +0.08 (+6.35%) Closing price 10/7/2025 03:58 PM EasternExtended Trading$1.25 -0.08 (-6.35%) As of 10/7/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EVGN vs. CARM, SNES, TOMZ, ENFY, BSLK, GURE, CNEY, NITO, TANH, and GAMCWShould you be buying Evogene stock or one of its competitors? The main competitors of Evogene include Carisma Therapeutics (CARM), Senestech (SNES), TOMI Environmental Solutions (TOMZ), Enlightify (ENFY), Bolt Projects (BSLK), Gulf Resources (GURE), CN Energy Group. (CNEY), N2OFF (NITO), Tantech (TANH), and Golden Arrow Merger (GAMCW). Evogene vs. Its Competitors Carisma Therapeutics Senestech TOMI Environmental Solutions Enlightify Bolt Projects Gulf Resources CN Energy Group. N2OFF Tantech Golden Arrow Merger Carisma Therapeutics (NASDAQ:CARM) and Evogene (NASDAQ:EVGN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability. Does the media favor CARM or EVGN? In the previous week, Carisma Therapeutics had 4 more articles in the media than Evogene. MarketBeat recorded 5 mentions for Carisma Therapeutics and 1 mentions for Evogene. Evogene's average media sentiment score of 0.38 beat Carisma Therapeutics' score of -0.43 indicating that Evogene is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Carisma Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Evogene 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders believe in CARM or EVGN? 44.3% of Carisma Therapeutics shares are held by institutional investors. Comparatively, 10.4% of Evogene shares are held by institutional investors. 6.9% of Carisma Therapeutics shares are held by company insiders. Comparatively, 7.4% of Evogene shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has better earnings and valuation, CARM or EVGN? Evogene has lower revenue, but higher earnings than Carisma Therapeutics. Evogene is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCarisma Therapeutics$19.63M0.56-$60.48M-$1.56-0.17Evogene$8.51M0.84-$16.49M-$2.25-0.59 Is CARM or EVGN more profitable? Evogene has a net margin of -211.61% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Evogene's return on equity.Company Net Margins Return on Equity Return on Assets Carisma Therapeutics-254.28% N/A -192.17% Evogene -211.61%-109.96%-38.47% Which has more risk and volatility, CARM or EVGN? Carisma Therapeutics has a beta of 2.06, suggesting that its stock price is 106% more volatile than the S&P 500. Comparatively, Evogene has a beta of 1.56, suggesting that its stock price is 56% more volatile than the S&P 500. Do analysts rate CARM or EVGN? Carisma Therapeutics presently has a consensus target price of $1.93, indicating a potential upside of 633.61%. Evogene has a consensus target price of $3.50, indicating a potential upside of 163.28%. Given Carisma Therapeutics' higher possible upside, equities analysts clearly believe Carisma Therapeutics is more favorable than Evogene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 1 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 2.50Evogene 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 SummaryCarisma Therapeutics beats Evogene on 9 of the 16 factors compared between the two stocks. Get Evogene News Delivered to You Automatically Sign up to receive the latest news and ratings for EVGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVGN vs. The Competition Export to ExcelMetricEvogeneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.71M$3.35B$6.12B$10.65BDividend YieldN/A2.29%5.70%4.75%P/E Ratio-0.5921.4185.6026.85Price / Sales0.84466.25612.81135.13Price / CashN/A47.6737.7861.77Price / Book0.4810.0613.256.70Net Income-$16.49M-$52.22M$3.30B$276.44M7 Day Performance15.40%4.25%3.87%2.48%1 Month Performance4.68%12.50%8.33%8.79%1 Year Performance-52.01%26.68%88.97%34.41% Evogene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVGNEvogene2.6848 of 5 stars$1.33+6.4%$3.50+163.3%-52.5%$6.71M$8.51M-0.59140Gap DownCARMCarisma Therapeutics2.4495 of 5 stars$0.29-2.5%$1.93+575.4%-72.2%$11.91M$19.63M-0.1820Short Interest ↑Gap UpSNESSenestech1.8046 of 5 stars$4.61+2.1%$10.00+117.2%+82.8%$22.75M$1.86M-0.8530TOMZTOMI Environmental Solutions3.064 of 5 stars$1.01+0.3%$3.50+245.5%+28.6%$20.34M$7.74M-4.4020Gap UpENFYEnlightify1.1494 of 5 stars$0.84-8.3%N/AN/A$13.23M$95.85M-0.67424Positive NewsGap UpBSLKBolt Projects0.3121 of 5 stars$3.83+0.4%N/A-67.8%$7.85M$1.37M-1.4712Positive NewsGUREGulf Resources0.5414 of 5 stars$0.58+0.4%N/A-41.1%$7.74M$7.66M-0.23420Positive NewsCNEYCN Energy Group.0.1353 of 5 stars$2.49-0.6%N/A-87.0%$7.48M$50.96M0.00160Positive NewsNITON2OFF1.6174 of 5 stars$3.65-4.8%N/A-45.9%$3.45M$210K0.002Gap DownTANHTantech0.1439 of 5 stars$1.68-0.9%N/A-75.4%$150K$42.94M0.0070GAMCWGolden Arrow MergerN/A$0.04-6.3%N/A-81.3%$0.00N/A0.0012Gap Down Related Companies and Tools Related Companies CARM Competitors SNES Competitors TOMZ Competitors ENFY Competitors BSLK Competitors GURE Competitors CNEY Competitors NITO Competitors TANH Competitors GAMCW Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVGN) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGet my No. 1 gold stock nowGold recently broke past $3,800 per ounce – setting yet another new all-time high. And Wall Street banks sa...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredU.S. Government Blocked NVIDIA’s Buyout… Here’s WhyThe U.S. government doesn't normally block billion-dollar tech deals. But when NVIDIA tried to acquire this...Behind the Markets | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evogene Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evogene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
